Effectiveness Both peptides deliver impressive results, with weight loss ranging from 22-24%
As India enters its GLP-1 era, the clinics that lead wont just prescribe the injection
Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance Hospira, Inc., a Pfizer company, is voluntarily recalling BACTERIOSTATIC WATER for Injection, USP, 30 mL, multi-dose vial, lot W20308, to the Hospital/Retail level
Tirzepatide, novel dual GIP/GLP-1 receptor agonist, is a new antihyperglycemic agent that was approved by the US Food and Drug Administration (United States) (FDA) in May 2022 that has demonstrated the highest HbA1C and weight reduction as a non-insulin agent
This results in reduced appetite and food cravings